Psychotomimesis Mediated by κ Opiate Receptors
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The κ opioid agonists are analgesics that seem to be free of undesired morphine-like effects. Their dysphoric actions observed with the κ agonist cyclazocine are thought to be mediated by an action at σ-phencyclidine receptors. The benzomorphan κ agonist MR 2033 is inactive at σ-phencyclidine receptors. In male subjects, the opiate-active (-)-isomer, but not the (+)-isomer, elicited dose-dependent dysphoric and psychotomimetic effects that were antagonized by naloxone. Thus, κ opiate receptors seem to mediate psychotomimetic effects. In view of the euphorigenic properties of μ agonists, our results imply the existence of opposed opioid systems affecting emotional and perceptual experiences.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“agonism of κ-opioid receptors were shown to produce depression-like symptoms in humans (Pfeiffer et al., 1986).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Pfeiffer et al., 1986
In the citing paper
“Nonetheless, the three receptor types have different behavioral domains, with MOR and DOR mediating generally positive motivation and affect, while KOR mediates generally negative motivation and aversion (Pfeiffer et al 1986; Shippenberg et al 1987; Pecina and Berridge 2000; McLaughlin et al 2003; for reviews see Van Ree et al 2000; Le Merrer et al 2009).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Pfeiffer et al 1986
In the citing paper
“Kappa receptor agonists induce anxiogenic and dysphoric effects in humans (141-143) and depressive-like behavior in animals (i.e., increased immobility in the forced swim test) (144, 145).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [141]
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
Pharmacologic effects of CI‐581, a new dissociative anesthetic, in man
Domino, E. F., Chodoff, P., & Corssen, G. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563279 · Cited by 748
Martin, W. R. (1983) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06637-2 · Cited by 648
Thrills in response to music and other stimuli
Goldstein, A. (1980) · Physiological Psychology · doi:10.3758/bf03326460 · Cited by 522
Mucha, R. F., & Herz, A. (1985) · Psychopharmacology · doi:10.1007/bf00432213 · Cited by 510
Self-citationThe binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/bf00495865 · Cited by 509
A CLASSIFICATION OF OPIATE RECEPTORS THAT MEDIATE ANTINOCICEPTION IN ANIMALS
TYERS, M. B. (1980) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1980.tb07041.x · Cited by 341
Opiate receptor binding sites in human brain
Pfeiffer, A., Pasi, A., Mehraein, P., & Herz, A. (1982) · Brain Research · doi:10.1016/0006-8993(82)91150-7 · Cited by 298
Self-citationPhencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.
Quirion, R., Hammer, R. P., Herkenham, M., & Pert, C. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5881 · Cited by 254
Research works printed but not linked: 6
- Jasinski, D. R., Drug Addiction 1: 216 (1977).
- MARTIN, W.R., PHARMACOL REV 35: 283 (1984).
- MARTIN, W.R., SUBSTANCE AND ALCOHOL ACTIONS/MISUSE 1: 269 (1980).
- Shearman, G. T., Drug Discrimination: Application in CNS Pharmacology: 37 (1982).
- VAUPEL, D.B., FAILURE OF NALTREXONE (NTX) TO ANTAGONIZE PHENCYCLIDINE (PCP) AND THE OPIOID SKF-10047 (SKF) IN THE DOG, FEDERATION PROCEEDINGS 41: 1333 (1982).
- Zerssen, D. V., Assessment of Depression: 270 (1985).
Cited by
Items 601–700 of 956
Zamarripa, C. A., Huskinson, S. L., Townsend, E. A., Prisinzano, T. E., Blough, B. E., Rowlett, J. K., & Freeman, K. B. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06486-5 · Cited by 12
Liu, H., Huang, R., Zhuo, Z., Zhang, X., Wu, L., Guo, Z., Wen, F., An, L., Yuan, H., Zhang, Y., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01709-4 · Cited by 12
Punishment and reinforcement by opioid receptor agonists in a choice procedure in rats
Minervini, V., Osteicoechea, D. C., Casalez, A., & France, C. P. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000436 · Cited by 12
Babwah, A. V. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110886 · Cited by 12
Knock-In Mouse Models to Investigate the Functions of Opioid Receptors in vivo
Degrandmaison, J., Rochon-Haché, S., Parent, J., & Gendron, L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.807549 · Cited by 12
Wagner, K., Valet, M., Kochs, E., Kriner, M., Tölle, T., & Sprenger, T. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108095811 · Cited by 12
Avila, J. A., Memos, N. K., Aslan, A., Andrejewski, T., Luine, V. N., & Serrano, P. A. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211048285 · Cited by 12
Brissett, D. I., Whistler, J. L., & van Rijn, R. M. (2011) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00022.x · Cited by 12
Distribution of Multiple Opioid Receptors in the Human Brain
Quirion, R., & Pilapil, C. (1991) · Elsevier eBooks · doi:10.1016/b978-0-12-490830-7.50010-2 · Cited by 12
Meyer, J. S., Inbar, S., & Rice, D. C. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(00)00323-3 · Cited by 12
Catheline, G., Guen, S. L., & Besson, J. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00153-3 · Cited by 12
Chen, C., Huang, P., Bland, K., Li, M., Zhang, Y., & Liu‐Chen, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835809 · Cited by 11
Yuferov, V. P., Butelman, E. R., Ho, A., Morgello, S., & Kreek, M. J. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-5 · Cited by 11
Liu, J. J., Chiu, Y.-T., Chen, C., Huang, P., Mann, M., & Liu‐Chen, L. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108324 · Cited by 11
Altshuler, J., & Spoelhof, B. (2013) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0b013e3182a10dbf · Cited by 11
Minervini, V., Dahal, S., & France, C. P. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235630 · Cited by 11
Clark, S. D. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_396 · Cited by 11
Black, J. W., & Meyer, L. H. (1992) · PubMed · Cited by 11
Valverde, O., Maldonado, R. J., & Kieffer, B. L. (1998) · CNS Drugs · doi:10.2165/00023210-199810010-00001 · Cited by 11
Opioid modulation of the discriminative stimulus produced by pentylenetetrazol
Emmett‐Oglesby, M. W., & Herz, A. (1987) · Psychopharmacology · doi:10.1007/bf00210836 · Cited by 11
Self-citationЗахарова, Е., Collins, S. L., Åberg, M., Kumar, A., Fernandez, J. B., & Izenwasser, S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.065 · Cited by 11
Husbands, S. M. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.12.1725 · Cited by 11
Cocaine Effects on Dopamine and Opioid Peptide Neural Systems: Implications for Human Cocaine Abuse
Hurd, Y. L. (1996) · PsycEXTRA Dataset · doi:10.1037/e495672006-006 · Cited by 11
van de Wetering, R., Ewald, A. W. M., Welsh, S., Kornberger, L., Williamson, S. E., McElroy, B. D., Butelman, E. R., Prisinzano, T. E., & Kivell, B. M. (2023) · Molecules · doi:10.3390/molecules28124848 · Cited by 10
Ma, Q., Wonnacott, S., Bailey, S., & Bailey, C. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015098 · Cited by 10
Jain, M. R., Patel, R. B., Prajapati, K. D., Vyas, P., Bandyopadhyay, D., Prajapati, V. M., Bahekar, R. H., Patel, P., Kawade, H. M., Kokare, D. M., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174961 · Cited by 10
Maguire, D. R., & France, C. P. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000184 · Cited by 10
Henriksen, G., Willoch, F., Talbot, P. S., & Wester, H. (2006) · Drug Development Research · doi:10.1002/ddr.20161 · Cited by 10
Chiba, S., Hayashida, M., Yoshikawa, M., Shu, H., Nishiyama, T., & Yamada, Y. (2009) · Journal of Anesthesia · doi:10.1007/s00540-008-0697-0 · Cited by 10
Yamada, M., Groshan, K., Phung, C.-T., Yamada, M., Hisamitsu, T., & Richelson, E. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(96)00139-8 · Cited by 10
Barnard, E. A. (1993) · Current Biology · doi:10.1016/0960-9822(93)90335-l · Cited by 10
Novel ORL1-selective antagonists with oral bioavailability and brain penetrability
Okamoto, O., Kobayashi, K., Kawamoto, H., Ito, S., Yoshizumi, T., Yamamoto, I., Hashimoto, M., Shimizu, A., Takahashi, H., Ishii, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.04.037 · Cited by 10
Kinouchi, K., Maeda, S., Saito, K., Inoki, R., Fukumitsu, K., & Yoshiya, I. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90231-8 · Cited by 10
Chemistry of Nonpeptide Opioids
Archer, S. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77460-7_11 · Cited by 10
Kappa opioid receptor control of motivated behavior revisited
Farahbakhsh, Z. Z., & Siciliano, C. A. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02226-9 · Cited by 9
Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates
Ko, M., & Husbands, S. M. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_419 · Cited by 9
Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA
Islam, A., Rahman, M. A., Brenner, M. B., Moore, A. R., Kellmyer, A., Buechler, H. M., DiGiorgio, F., Verchio, V., McCracken, L., Sumi, M., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00066 · Cited by 9
Effects of remifentanil/histamine mixtures in rats responding under a choice procedure
Minervini, V., Tye, C. B., Ghodrati, S., & France, C. P. (2021) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000610 · Cited by 9
Role of Opioid Receptors in the Reinstatement of Opioid-Seeking Behavior: An Overview
Fattore, L., Fadda, P., Antinori, S., & Fratta, W. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1708-2_24 · Cited by 9
Ketamina: Nuevas observaciones sobre su consumo, consumidores y efectos
Jansen, K. L. R., & Theron, L. (2003) · Adicciones · doi:10.20882/adicciones.458 · Cited by 9
The effect of the nonselective opioid antagonist diprenorphine on vasopressin secretion in the rat
Iwasaki, Y., Gaskill, M. B., Boss, C., & Robertson, G. L. (1994) · Endocrinology · doi:10.1210/endo.134.1.8275962 · Cited by 9
High‐Dose Naloxone in Older Normal Subjects: Implications for Alzheimer's Disease
Tariot, P. N., Gross, M., Sunderland, T., Cohen, M. R., Weingartner, H., Murphy, D. L., & Cohen, R. M. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb07168.x · Cited by 9
Opioid Modulation of Psychomotor Stimulant Effects
Shippenberg, T. S., & Chefer, V. I. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-343-9_7 · Cited by 9
McFarland, K., & Kalivas, P. W. (2003) · Wiley eBooks · doi:10.1002/0471264385.wei0314 · Cited by 9
Windisch, K. A., Morochnik, M., Reed, B., & Kreek, M. J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108590 · Cited by 8
Meariman, J. K., Sutphen, J. C., Gao, J., Mercante, D. E., & Kapusta, D. R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106470 · Cited by 8
Morrison, F. G., Orden, L. J. V., Zeitz, K., Kuijer, E. J., Smith, S. L., Heal, D. J., & Wallace, T. L. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110037 · Cited by 8
Zhao, M., Wang, M.-Y., Ma, L., Ahmad, K. A., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.620926 · Cited by 8
Butorphanol induces anxiety-like behaviour and distress in piglets
Pavlovsky, V. H., Corona, D., Hug, P. J., Kümmerlen, D., Graage, R., & Bettschart‐Wolfensberger, R. (2021) · Schweizer Archiv für Tierheilkunde · doi:10.17236/sat00309 · Cited by 8
Nanobodies as sensors of GPCR activation and signaling
Daibani, A. E., & Che, T. (2021) · Methods in cell biology · doi:10.1016/bs.mcb.2021.06.008 · Cited by 8
Yoshizawa, K., Narita, M., Mori, T., Miyatake, M., Isotani, K., Tomiyasu, S., Tsukiyama, Y., & Suzuki, T. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00257.x · Cited by 8
Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions
Butelman, E. R., & Kreek, M. J. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_9 · Cited by 8
Age as a factor in stress and alcohol interactions: A critical role for the kappa opioid system
Diaz, M. R., Przybysz, K. R., & Rouzer, S. K. (2017) · Alcohol · doi:10.1016/j.alcohol.2017.10.002 · Cited by 8
Varastehmoradi, B., Smith, K. L., Müller, H. K., Elfving, B., Sánchez, C., & Wegener, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.03.010 · Cited by 8
Borderline personality disorder - a dysregulation of the endogenous opioid system?
Bandelow, B., Schmahl, C. G., Falkai, P., & Wedekind, D. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)72713-4 · Cited by 8
Kumar, V., Guo, D., Marella, M. A., Cassel, J. A., DeHaven, R. N., Daubert, J. D., & Mansson, E. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.11.116 · Cited by 8
Kaufman, M. J., Janes, A. C., Frederick, B. B., Brimson-Théberge, M., Tong, Y., McWilliams, S. B., Bear, A., Gillis, T. E., Schrode, K. M., Renshaw, P. F., et al. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0033062 · Cited by 8
Rasakham, K., McGillivray, K., & Liu‐Chen, L. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.07.040 · Cited by 8
Picker, M. J., Massie, C. A., & Dykstra, L. A. (1987) · Psychopharmacology · doi:10.1007/bf00179940 · Cited by 8
Reed, B., Butelman, E. R., Fry, R. S., Kimani, R. W., & Kreek, M. J. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.245 · Cited by 8
Smart, K. A., Yttredahl, A. A., Oquendo, M. A., Mann, J. J., Hillmer, A. T., Carson, R. E., & Miller, J. M. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01729-5 · Cited by 7
Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine
Hennessy, M. R., Creed, S. M., Gutridge, A. M., Rusali, L. E., Luo, D., Sepehri, B., Rhoda, E. S., Villegas, J. A., van Rijn, R. M., & Riley, A. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00736 · Cited by 7
Salvia divinorum: enigma psicofarmacológico y resquicio mente-cuerpo
Díaz, J. L. (2014) · Salud Mental · doi:10.17711/sm.0185-3325.2014.022 · Cited by 7
Pani, P., Maremmani, A. G. I., Pacini, M., Trogu, E., Gessa, G. L., Ruiz, P., & Maremmani, I. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061913 · Cited by 7
Yamaguchi, M., Miyano, K., Hirayama, S., Karasawa, Y., Ohshima, K., Uezono, E., Komatsu, A., Nonaka, M., Fujii, H., Yamaguchi, K., et al. (2022) · Molecules · doi:10.3390/molecules27207065 · Cited by 7
The Legal Highs of Novel Drugs of Abuse
Pompei, P. (2016) · Journal of Drug Abuse · doi:10.21767/2471-853x.100025 · Cited by 7
Hughes, E. M., Thornton, A. M., Kerr, D. M., Smith, K. L., Sánchez, C., Kelly, J. P., Finn, D. P., & Roche, M. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.07.055 · Cited by 7
Shen, S., & Ingenito, A. J. (1999) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357991776985 · Cited by 7
Differential Sensitivity to Morphine Challenge in Migraine Sufferers and Headache-Exempt Subjects
Nicolodi, M. (1996) · Cephalalgia · doi:10.1046/j.1468-2982.1996.1605297.x · Cited by 7
Psychotimimetic effects and stigma ligands
Connick, J. H., Fox, P., & Nicholson, D. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90006-t · Cited by 7
Zhai, Q., & Ingenito, A. J. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199806000-00002 · Cited by 7
Groves, S., Nutt, D. J., Vieta, E., Bernardo, M., & Vallejo, J. (1991) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.470060113 · Cited by 7
KOR agonists for the treatment and/or prevention of opioid use disorder and cocaine use disorder
Liu‐Chen, L., & Huang, P. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174056 · Cited by 6
Structural basis of opioid receptor activation by PCP and ketamine
Jiang, Q., Han, J., Fine, E. J., Ramos‐Gonzalez, N., Rangari, V. A., Ruiz, M. V., Critz, M., Suomivuori, C., Wang, J., Albert, T. L., et al. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01839-y · Cited by 6
Effects of sex and hydration status on kappa opioid receptor‐mediated diuresis in rats
Lalji, H. M., Bailey, C. P., Husbands, S. M., & Bailey, S. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14008 · Cited by 6
Hu, S., Yu, H., Liu, Y., Xue, T., & Zhang, H. (2013) · Journal of Molecular Modeling · doi:10.1007/s00894-013-1839-3 · Cited by 6
Negative Emotions and Alcohol Use Disorder Treatment
Kushner, M. G., & Anker, J. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813125-1.00063-5 · Cited by 6
Differential barcoding of opioid receptors trafficking
Degrandmaison, J., Grisé, O., Parent, J., & Gendron, L. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24949 · Cited by 6
Brenner, G. J., Mao, J., & Rosow, C. E. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-322-4_24 · Cited by 6
Mori, T., Yoshizawa, K., Ueno, T., Nishiwaki, M., Shimizu, N., Shibasaki, M., Narita, M., & Suzuki, T. (2013) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283635f6b · Cited by 6
Effect of Repetitive Transcranial Magnetic Stimulation on Malignant Visceral Pain
Khedr, E. M., Mostafa, M. G., Kotb, H. I., Mohamad, M. F., Bakry, R., & Kamal, S. M. (2015) · Neuroenterology · doi:10.4303/ne/235927 · Cited by 6
Solution structure of nocistatin, a new peptide analgesic
Crescenzi, O., Guerrini, R., Picone, D., Salvadori, S., Tancredi, T., & Temussi, P. A. (2000) · Biopolymers · doi:10.1002/(sici)1097-0282(200003)53:3<257::aid-bip5>3.0.co;2-l · Cited by 6
Zur Neurobiologie und Psychopathologie süchtigen Verhaltens
Böning, J. (1991) · Suchtproblematik · doi:10.1007/978-3-642-95644-7_1 · Cited by 6
Infusion of γ2-MSH produce a conditioned taste aversion in morphine-dependent rats
Mucha, R. F., & van Ree, J. M. (1989) · Psychopharmacology · doi:10.1007/bf00634469 · Cited by 6
That deep internal voice: Controlled administration of Salvia divinorum
Addy, P. H. (n.d.) · ProQuest Demo Repository · Cited by 6
Behavioral Studies in Nonhuman Primates: Focus on Models of Substance Use Disorders
Johnson, B., Norman, C., Minkiewicz, M., & Nader, M. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.23967-9 · Cited by 6
Neurobiology of negative reinforcement as a driving force in alcohol addiction
Vendruscolo, L. F., & Koob, G. F. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.038 · Cited by 5
Sheveleva, M. V., Lebedev, A. A., Roik, R. O., & Shabanov, P. D. (2013) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1133-19 · Cited by 5
Ide, S., Hirai, T., Muto, T., Yamakawa, T., & Ikeda, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-45584-4 · Cited by 5
Varman, D. R., Jayanthi, L. D., & Ramamoorthy, S. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.0171-25.2025 · Cited by 5
Pierzchała, K., Scanes, C. G., Dziedzicka‐Wasylewska, M., Wieczorek, M., & Oeltgen, P. R. (2017) · Folia Biologica · doi:10.3409/fb65_4.199 · Cited by 5
Huang, P., Gentile, T. A., Muschamp, J. W., & Liu‐Chen, L. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05227-7 · Cited by 5
Relevance of the Kappa Dynorphin System to Schizophrenia and Its Therapeutics
Abi‐Dargham, A. (2021) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20210015 · Cited by 5
Wang, X., Chen, Y., Wang, Z., Zhang, Y., Cui, Z., & Sun, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.665107 · Cited by 5
Huskinson, S. L., Platt, D. M., Smith, Z. R., Doyle, W. S., Zamarripa, C. A., Dunaway, K., Prisinzano, T. E., & Freeman, K. B. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110953 · Cited by 5
Halberstadt, A. L., Hyun, J. S., Ruderman, M. A., & Powell, S. B. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.05.009 · Cited by 5
Salles, J., Ponté, C., & Schmitt, L. (2019) · Journal of Dual Diagnosis · doi:10.1080/15504263.2019.1574367 · Cited by 5
Maqoud, F., Fabio, G., Ciliero, N., Antonacci, M., Mastrangelo, F., Sammarruco, G., Cataldini, R., Schirosi, G., Fazio, S. D., & Tricarico, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020461 · Cited by 5
The Role of the Dynorphin/Kappa Opioid Receptor System in the Actions of Alcohol
Sureshkumar, K., Go, J., Tran, M., Malhotra, S., Ahmad, S. M., & Lutfy, K. (2022) · Psychoactives · doi:10.3390/psychoactives1020006 · Cited by 5
Przewłocki, R., & Almeida, O. F. X. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00008-0 · Cited by 5
Metadata
- Authors
- Pfeiffer, A., Brantl, V., Herz, A., & Emrich, H. M.
- Affiliations
- LMU Klinikum (DE)
- Boehringer Ingelheim (Germany) (DE)
- Max Planck Society (DE)
- Max Planck Institute of Psychiatry (DE)
- ORCID
- Pfeiffer, Andreas
- Venue
- Science
- Published
- 1986-08-15
- Volume
- 233
- Issue
- 4765
- Pages
- 774-776
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2032643119
- Cited by
- 857
- References
- 30
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 23 · 2023: 17 · 2022: 18 · 2021: 38 · 2020: 42 · 2019: 21 · 2018: 27 · 2017: 24 · 2016: 37 · 2015: 38 · 2014: 30 · 2013: 35 · 2012: 41
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- psychotomimetic effects, kappa opioid receptor, kappa opioid receptor agonists, cyclazocine, naloxone antagonism, stereoisomers, mu-opioid receptor agonists, euphoria, analgesia
- MeSH terms
- Adult, Anxiety, Benzomorphans, Humans, Male, Middle Aged, Morphinans, Naloxone, Personality Tests, Phencyclidine, Receptors, Opioid, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.